We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
California’s proposed prescription drug program wrongly imposes artificial price controls that could undermine future innovations, the drug industry says.
The international drug development services company formerly known as SFBC International announced Aug. 28 that it has formally changed its corporate name to PharmaNet Development Group.
Merck’s recent losses in federal and state court signal not only flaws in the company’s legal strategy in fighting thousands of lawsuits involving its pain-relief drug Vioxx, but also more liability than originally anticipated, a financial analyst says.
The Irish Medical Devices Association (IMDA), which falls within the Irish Business and Employers Confederation, has called for “a concerted effort to be made across Europe” to establish a system to enable small EU-based device and diagnostic companies to benefit from fee reductions when registering new product applications with the FDA.
An aging U.S. population and increasing rates of obesity are contributing to a positive market outlook for devices to treat and monitor sleep apnea, analysts say.
While Merck is fighting thousands of lawsuits filed by former patients who claim its pain drug Vioxx causes heart attack and stroke, a study has found that Celebrex, a pain drug made by Pfizer that belongs to the same class of drugs as Vioxx, may slow or prevent the onset of colon cancer.
The National Institute of Allergy and Infectious Diseases, a division of the NIH, has awarded the University of Pittsburgh a $1.3 million grant to develop an avian flu vaccine that could fight more than one strain of the virus effectively, according to the university.
Schering-Plough has entered an agreement with the Department of Justice (DOJ) to settle the federal government’s investigation into the company’s sales, marketing and clinical trial activities.